Literature DB >> 21972895

Mice deficient in endothelin-converting enzyme-2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord.

Lydia K Miller1, Xiaowen Hou, Ramona M Rodriguiz, Khatuna Gagnidze, Jonathan V Sweedler, William C Wetsel, Lakshmi A Devi.   

Abstract

An increasing body of evidence suggests that endothelin-converting enzyme-2 (ECE-2) is a non-classical neuropeptide processing enzyme. Similar to other neuropeptide processing enzymes, ECE-2 exhibits restricted neuroendocrine distribution, intracellular localization, and an acidic pH optimum. However, unlike classical neuropeptide processing enzymes, ECE-2 exhibits a non-classical cleavage site preference for aliphatic and aromatic residues. We previously reported that ECE-2 cleaves a number of neuropeptides at non-classical sites in vitro; however its role in peptide processing in vivo is poorly understood. Given the recognized roles of neuropeptides in pain and opiate responses, we hypothesized that ECE-2 knockout (KO) mice might show altered pain and morphine responses compared with wild-type mice. We find that ECE-2 KO mice show decreased response to a single injection of morphine in hot-plate and tail-flick tests. ECE-2 KO mice also show more rapid development of tolerance with prolonged morphine treatment and fewer signs of naloxone-precipitated withdrawal. Peptidomic analyses revealed changes in the levels of a number of spinal cord peptides in ECE-2 KO as compared to wild-type mice. Taken together, our findings suggest a role for ECE-2 in the non-classical processing of spinal cord peptides and morphine responses; however, the precise mechanisms through which ECE-2 influences morphine tolerance and withdrawal remain unclear.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21972895      PMCID: PMC3217172          DOI: 10.1111/j.1471-4159.2011.07513.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  49 in total

1.  Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues.

Authors:  Ashani T Weeraratna; Audrey Kalehua; Isoke Deleon; Dorothy Bertak; Gregory Maher; Michael S Wade; Ana Lustig; Kevin G Becker; William Wood; Douglas G Walker; Thomas G Beach; Dennis D Taub
Journal:  Exp Cell Res       Date:  2006-11-01       Impact factor: 3.905

2.  Exosomes are released by cultured cortical neurones.

Authors:  J Fauré; G Lachenal; M Court; J Hirrlinger; C Chatellard-Causse; B Blot; J Grange; G Schoehn; Y Goldberg; V Boyer; F Kirchhoff; G Raposo; J Garin; R Sadoul
Journal:  Mol Cell Neurosci       Date:  2006-01-30       Impact factor: 4.314

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

4.  Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro.

Authors:  H Beck; G Schwarz; C J Schröter; M Deeg; D Baier; S Stevanovic; E Weber; C Driessen; H Kalbacher
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

5.  A new endogenous opioid peptide from bovine adrenal medulla: isolation and amino acid sequence of a dodecapeptide (BAM-12P).

Authors:  K Mizuno; N Minamino; K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1980-08-29       Impact factor: 3.575

6.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 7.  Exosomes as intercellular signalosomes and pharmacological effectors.

Authors:  Michel Record; Caroline Subra; Sandrine Silvente-Poirot; Marc Poirot
Journal:  Biochem Pharmacol       Date:  2011-03-01       Impact factor: 5.858

Review 8.  The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction.

Authors:  Joanna Mika; Ilona Obara; Barbara Przewlocka
Journal:  Neuropeptides       Date:  2011-04-08       Impact factor: 3.286

9.  Cathepsin G, and not the asparagine-specific endoprotease, controls the processing of myelin basic protein in lysosomes from human B lymphocytes.

Authors:  Timo Burster; Alexander Beck; Eva Tolosa; Viviana Marin-Esteban; Olaf Rötzschke; Kirsten Falk; Alfred Lautwein; Michael Reich; Jens Brandenburg; Gerold Schwarz; Heinz Wiendl; Arthur Melms; Rainer Lehmann; Stefan Stevanovic; Hubert Kalbacher; Christoph Driessen
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

10.  Neuropeptidomics of the supraoptic rat nucleus.

Authors:  Adriana Bora; Suresh P Annangudi; Larry J Millet; Stanislav S Rubakhin; Andrew J Forbes; Neil L Kelleher; Martha U Gillette; Jonathan V Sweedler
Journal:  J Proteome Res       Date:  2008-09-25       Impact factor: 4.466

View more
  4 in total

1.  Identification of Alzheimer's disease-associated rare coding variants in the ECE2 gene.

Authors:  Xinxin Liao; Fang Cai; Zhanfang Sun; Yun Zhang; Juelu Wang; Bin Jiao; Jifeng Guo; Jinchen Li; Xixi Liu; Lina Guo; Yafang Zhou; Junling Wang; Xinxiang Yan; Hong Jiang; Kun Xia; Jiada Li; Beisha Tang; Lu Shen; Weihong Song
Journal:  JCI Insight       Date:  2020-02-27

Review 2.  Quantitation of endogenous peptides using mass spectrometry based methods.

Authors:  Elena V Romanova; Sarah E Dowd; Jonathan V Sweedler
Journal:  Curr Opin Chem Biol       Date:  2013-06-18       Impact factor: 8.822

3.  Endothelin-converting enzyme 2 differentially regulates opioid receptor activity.

Authors:  A Gupta; W Fujita; I Gomes; E Bobeck; L A Devi
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

4.  Nociceptor-Enriched Genes Required for Normal Thermal Nociception.

Authors:  Ken Honjo; Stephanie E Mauthner; Yu Wang; J H Pate Skene; W Daniel Tracey
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.